

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/172916 A3

(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 14/705 (2006.01)
C07K 14/435 (2006.01) C12N 15/06 (2006.01)
C07K 16/30 (2006.01) C12K 16/28 (2006.01)

(21) International Application Number:

PCT/US2023/063868

(22) International Filing Date:

07 March 2023 (07.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/317,935 08 March 2022 (08.03.2022) US

(71) Applicant: SYNTHKINE, INC. [US/US]; 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(72) Inventors: PENAFLOR-ASPURIA, Paul-Joseph; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). ROKKAM, Dcepti; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(74) Agent: HINSCH, Matthew E.; KILPATRICK TOWNSEND & STOCKTON LLP, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

(88) Date of publication of the international search report:

16 May 2024 (16.05.2024)

(15) Information about Correction:

see Notice of 25 January 2024 (25.01.2024)

(54) Title: ORTHOGONAL GPC3 CHIMERIC ANTIGEN RECEPTOR T CELLS




FIG. 1

(57) Abstract: Engineered T cells are provided that express (a) a chimeric antigen receptor wherein the antigen binding domain of the CAR binds to human GPC3 ("a GPC-CAR"); and (b) an orthogonal receptor. Also provided are methods of making and using such engineered T cells.

WO 2023/172916 A3